Page 834 - Clinical Immunology_ Principles and Practice ( PDFDrive )

806 Part SIX Systemic Immune Diseases

34. Calhan T, et al. Antineutrophil cytoplasmic antibody frequency in chronic vasculitis: follow-up data from European Vasculitis Study Group clinical
hepatitis B patients. Dis Markers 2014;2014:982150. trials. Ann Rheum Dis 2011;70(8):1415–21.
35. Kain R, et al. Molecular mimicry in pauci-immune focal necrotizing 56. Guma M, et al. Frequency of antineutrophil cytoplasmic antibody in
glomerulonephritis. Nat Med 2008;14(10):1088–96. Graves’ disease patients treated with methimazole. J Clin Endocrinol
36. Hurtado PR, et al. CpG oligodeoxynucleotide stimulates production of Metab 2003;88(5):2141–6.
anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. 57. Lenert P, Icardi M, Dahmoush L. ANA (+) ANCA (+) systemic vasculitis
BMC Immunol 2008;9:34. associated with the use of minocycline: case-based review. Clin
37. Noh JY, Yasuda S, Sato S, et al. Clinical characteristics of myeloperoxidase Rheumatol 2013;32(7):1099–106.
antineutrophil cytoplasmic antibody-associated vasculitis caused by 58. Zhang AH, et al. Inhibition of oxidation activity of myeloperoxidase
antithyroid drugs. J Clin Endocrinol Metab 2009;94(8):2806–11. (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from
38. Waldhauser L, Uetrecht J. Oxidation of propylthiouracil to reactive patients with PTU-induced vasculitis. Clin Immunol 2007;122(2):
metabolites by activated neutrophils. Implications for agranulocytosis. 187–93.
Drug Metab Dispos 1991;19(2):354–9. 59. Denissen NH, et al. Can sulfasalazine therapy induce or exacerbate
39. Nakazawa D, et al. Abnormal conformation and impaired degradation of Wegener’s granulomatosis? Scand J Rheumatol 2008;37(1):72–4.
propylthiouracil-induced neutrophil extracellular traps: implications of 60. Takahashi K, Oharaseki T, Yokouchi Y. Update on etio and
disordered neutrophil extracellular traps in a rat model of immunopathogenesis of Kawasaki disease. Curr Opin Rheumatol
myeloperoxidase antineutrophil cytoplasmic antibody-associated 2014;26(1):31–6.
vasculitis. Arthritis Rheum 2012;64(11):3779–87. 61. Lin YJ, et al. Genetic variants in PLCB4/PLCB1 as susceptibility loci for
40. Berman M, Paran D, Elkayam O. Cocaine-Induced Vasculitis. Rambam coronary artery aneurysm formation in Kawasaki disease in Han Chinese
Maimonides Med J 2016;7(4). in Taiwan. Sci Rep 2015;5:14762.
41. Wiesner O, et al. Antineutrophil cytoplasmic antibodies reacting with 62. Onouchi Y, et al. ITPKC and CASP3 polymorphisms and risks for IVIG
human neutrophil elastase as a diagnostic marker for cocaine-induced unresponsiveness and coronary artery lesion formation in Kawasaki
midline destructive lesions but not autoimmune vasculitis. Arthritis disease. Pharmacogenomics J 2013;13(1):52–9.
Rheum 2004;50(9):2954–65. 63. Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin
42. Tsurikisawa N, et al. Decreases in the numbers of peripheral blood Rheumatol 2010;22(5):551–60.
regulatory T cells, and increases in the levels of memory and activated B 64. Gorelik M, et al. Plasma follistatin-like protein 1 is elevated in Kawasaki
cells, in patients with active eosinophilic granulomatosis and polyangiitis. disease and may predict coronary artery aneurysm formation. J Pediatr
J Clin Immunol 2013;33(5):965–76. 2012;161(1):116–19.
43. Abdulahad WH, Boots AMH, Kallenberg CGM. FoxP3(+) CD4(+) T cells 65. Lin IC, et al. Augmented TLR2 expression on monocytes in both human
in systemic autoimmune diseases: the delicate balance between true Kawasaki disease and a mouse model of coronary arteritis. PLoS ONE
regulatory T cells and effector Th-17 cells. Rheumatology 2012;7(6):e38635.
2011;50(4):646–56. 66. Jia S, et al. The T helper type 17/regulatory T cell imbalance in
44. Marinaki S, et al. Persistent T-cell activation and clinical correlations in patients with acute Kawasaki disease. Clin Exp Immunol
patients with ANCA-associated systemic vasculitis. Nephrol Dial 2010;162(1):131–7.
Transplant 2006;21(7):1825–32. 67. Rowley AH, et al. The transcriptional profile of coronary arteritis in
45. Holden NJ, et al. ANCA-stimulated neutrophils release BLyS and promote Kawasaki disease. BMC Genomics 2015;16:1076.
B cell survival: a clinically relevant cellular process. Ann Rheum Dis 68. Leung DY, et al. Prevalence of superantigen-secreting bacteria in patients
2011;70(12):2229–33. with Kawasaki disease. J Pediatr 2002;140(6):742–6.
46. Nakazawa D, et al. Enhanced Formation and Disordered Regulation of 69. Schulte DJ, et al. Involvement of innate and adaptive immunity in a
NETs in Myeloperoxidase-ANCA-Associated Microscopic Polyangiitis. J murine model of coronary arteritis mimicking Kawasaki disease. J
Am Soc Nephrol 2014;25(5):990–7. Immunol 2009;183(8):5311–18.
47. Yuan J, et al. C5a and its receptors in human anti-neutrophil cytoplasmic 70. Cid MC, et al. Immunohistochemical characterization of inflammatory
antibody (ANCA)-associated vasculitis. Arthritis Res Ther 2012;14(3). cells and immunologic activation markers in muscle and nerve biopsy
48. Chen SF, et al. Plasma complement factor H is associated with disease specimens from patients with systemic polyarteritis nodosa. Arthritis
activity of patients with ANCA-associated vasculitis. Arthritis Res Ther Rheum 1994;37(7):1055–61.
2015;17. 71. Yalcinkaya F, et al. Prevalence of the MEFV gene mutations in childhood
49. Fukui S, et al. Antineutrophilic cytoplasmic antibody-associated vasculitis polyarteritis nodosa. J Pediatr 2007;151(6):675–8.
with hypocomplementemia has a higher incidence of 72. Sansonno D, et al. Hepatitis C virus infection, cryoglobulinaemia, and
serious organ damage and a poor prognosis. Medicine (Baltimore) beyond. Rheumatology 2007;46(4):572–8.
2016;95(37). 73. Varricchi G, et al. Interleukin-5 pathway inhibition in the treatment of
50. Choi HK, Merkel PA, Niles JL. ANCA-positive vasculitis associated with eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin
allopurinol therapy. Clin Exp Rheumatol 1998;16(6):743–4. Allergy Clin Immunol 2016;16(2):186–200.
51. Hirohama D, et al. Development of myeloperoxidase-antineutrophil 74. Craven A, et al. ACR/EULAR-endorsed study to develop Diagnostic and
cytoplasmic antibody-associated renal vasculitis in a patient receiving Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol
treatment with anti-tumor necrosis factor-alpha. Mod Rheumatol 2013;17(5):619–21.
2010;20(6):602–5. 75. Luqmani R, Ponte C. ANCA associated vasculitides and polyarteritis
52. Jarraya F, et al. Myeloperoxidase-antineutrophil cytoplasmic nodosa. In: Hachulla E, Bijlsma JWJ, editors. EULAR Textbook on
antibody-positive crescentic glomerulonephritis associated with rheumatic diseases. BMJ Publishing Group Ltd; 2015. p. 717–53.
benzylthiouracil therapy: report of the first case. Nephrol Dial Transplant 75a. Stahelin L, et al. Cocaine-induced midline destruction lesions with
2003;18(11):2421–3. positive ANCA test mimicking Wegener’s granulomatosis. Rev Bras
53. Bienaime F, et al. D-Penicillamine-induced ANCA-associated crescentic Reumatol 2012;52(3):431–7.
glomerulonephritis in Wilson disease. Am J Kidney Dis 2007;50(5): 76. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in
821–5. ANCA-associated vasculitis. Ann Rheum Dis 2011;70(3):488–94.
54. Carmona-Rivera C, Purmalek MM, Moore E, et al. A role for muscarinic 77. Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse:
receptors in neutrophil extracellular trap formation and levamisole- useful in patients with renal involvement but not in patients with
induced autoimmunity. JCI Insight 2017;2(3):e89780. nonrenal disease. J Am Soc Nephrol 2015;26(3):537–42.
55. Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in 78. Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR Standards,
patients treated for antineutrophil cytoplasm antibody-associated Guidelines and Audit Working Group BSR and BHPR guideline for the